Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Anti-CD22 CAR-T combined with anti-CD19 CAR-T cells in the treatment of relapsed or refractory acute B lymphocytic leukemia with severe cytokine release syndrome: two cases report and literature review].
Gao LL, Huang L, Wang N, Wang GX, Zhou XX, Li TJ, Hong ZY, Meng L, Zhou JF. Gao LL, et al. Among authors: wang gx, wang n. Zhonghua Xue Ye Xue Za Zhi. 2019 Sep 14;40(9):780-782. doi: 10.3760/cma.j.issn.0253-2727.2019.09.016. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31648485 Free PMC article. Review. Chinese. No abstract available.
A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, Wang D, Wang J, Jiang L, Xu H, Xu J, Zhou X, Hong Z, Wang N, Huang L, Zhang S, Chen L, Mao X, Xiao M, Zhang W, Meng L, Cao Y, Zhang T, Li J, Zhou J. Li C, et al. Among authors: wang j, wang n, wang d, wang q. Clin Transl Med. 2021 Mar;11(3):e346. doi: 10.1002/ctm2.346. Clin Transl Med. 2021. PMID: 33784005 Free PMC article. Clinical Trial.
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y, Xiao Y, Wang N, Wang G, Huang L, Hong Z, Meng L, Zhou X, Wang J, Yang Y, Xu H, Zhang S, Xiao M, Chen L, Zheng M, Li C, Mao X, Gu C, Zhang T, Zhang Y, Zhou J. Cao Y, et al. Among authors: wang g, wang j, wang n. Transplant Cell Ther. 2021 Nov;27(11):910.e1-910.e11. doi: 10.1016/j.jtct.2021.08.012. Epub 2021 Aug 20. Transplant Cell Ther. 2021. PMID: 34425260 Free article.
[Immunophenotypic changes after central recurrence in a case of Ph positive B-ALL receiving sequential infusion of anti-CD22 and anti-CD19 CAR-T therapy].
Mao X, He C, Liu SY, Wang CY, Zhu L, Wang N, Xiao M, Zhou JF, Xiao Y. Mao X, et al. Among authors: wang cy, wang n. Zhonghua Xue Ye Xue Za Zhi. 2019 Mar 14;40(3):246. doi: 10.3760/cma.j.issn.0253-2727.2019.03.017. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 30929396 Free PMC article. Chinese. No abstract available.
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.
Wang J, Shen K, Mu W, Li W, Zhang M, Zhang W, Li Z, Ge T, Zhu Z, Zhang S, Chen C, Xing S, Zhu L, Chen L, Wang N, Huang L, Li D, Xiao M, Zhou J. Wang J, et al. Among authors: wang n. Front Immunol. 2022 Apr 27;13:873789. doi: 10.3389/fimmu.2022.873789. eCollection 2022. Front Immunol. 2022. PMID: 35572515 Free PMC article.
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J, Cao Y, Zhang Q, Liu W, Zhou X, Ming X, Meng F, Zhang Y, Li C, Huang L, Wei J, Zheng M, Zhang S, Zhang T, Zhu X, Wang N, Wang J, Wang G, Zhou J, Liu B, Xiao Y. Wu J, et al. Among authors: wang g, wang j, wang n. Front Immunol. 2022 May 20;13:879983. doi: 10.3389/fimmu.2022.879983. eCollection 2022. Front Immunol. 2022. PMID: 35669773 Free PMC article.
20,231 results
You have reached the last available page of results. Please see the User Guide for more information.